IL141064A0 - Tnf-derived peptides for use in treating oedema - Google Patents
Tnf-derived peptides for use in treating oedemaInfo
- Publication number
- IL141064A0 IL141064A0 IL14106499A IL14106499A IL141064A0 IL 141064 A0 IL141064 A0 IL 141064A0 IL 14106499 A IL14106499 A IL 14106499A IL 14106499 A IL14106499 A IL 14106499A IL 141064 A0 IL141064 A0 IL 141064A0
- Authority
- IL
- Israel
- Prior art keywords
- tnf
- oedema
- alpha
- present
- derived peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010030113 Oedema Diseases 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 206010037423 Pulmonary oedema Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102000057041 human TNF Human genes 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98870180 | 1998-08-14 | ||
| EP98870198 | 1998-09-18 | ||
| EP98870222 | 1998-10-21 | ||
| PCT/EP1999/005806 WO2000009149A1 (en) | 1998-08-14 | 1999-08-10 | Tnf-derived peptides for use in treating oedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL141064A0 true IL141064A0 (en) | 2002-02-10 |
Family
ID=27239778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14106499A IL141064A0 (en) | 1998-08-14 | 1999-08-10 | Tnf-derived peptides for use in treating oedema |
| IL141064A IL141064A (en) | 1998-08-14 | 2001-01-24 | Use of tnf-derived peptides for the manufacture of a medicament for treating oedema |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL141064A IL141064A (en) | 1998-08-14 | 2001-01-24 | Use of tnf-derived peptides for the manufacture of a medicament for treating oedema |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030105021A1 (enExample) |
| EP (3) | EP1105152A1 (enExample) |
| JP (1) | JP4542266B2 (enExample) |
| CN (1) | CN1181886C (enExample) |
| AT (2) | ATE395072T1 (enExample) |
| AU (1) | AU764992B2 (enExample) |
| BR (1) | BR9912899A (enExample) |
| CA (1) | CA2334941C (enExample) |
| CZ (1) | CZ302862B6 (enExample) |
| DE (2) | DE69938743D1 (enExample) |
| DK (1) | DK1264599T3 (enExample) |
| ES (1) | ES2296872T3 (enExample) |
| HU (1) | HU227661B1 (enExample) |
| IL (2) | IL141064A0 (enExample) |
| NZ (1) | NZ509604A (enExample) |
| PL (1) | PL203706B1 (enExample) |
| PT (1) | PT1264599E (enExample) |
| TR (1) | TR200100338T2 (enExample) |
| WO (1) | WO2000009149A1 (enExample) |
| ZA (1) | ZA200100656B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227661B1 (hu) | 1998-08-14 | 2011-10-28 | Rudolf Lucas Dr | TNF-eredetû peptidek ödéma kezelésére |
| CA2575513C (en) * | 2004-08-06 | 2014-09-16 | Altana Pharma Ag | Composition comprising a pulmonary surfactant and a tnf-derived peptide |
| EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
| AT506151B1 (de) * | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Fusionsprotein |
| AT506150B1 (de) * | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Zyklisches und cystein-freies peptid |
| AT507953B1 (de) * | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
| AT509267A1 (de) | 2010-01-14 | 2011-07-15 | Apeptico Forschung & Entwicklung Gmbh | Organische verbindungen zur regulierung von vektoriellen ionenkanälen |
| DK2397151T3 (en) | 2010-06-21 | 2015-05-18 | Apeptico Forschung & Entwicklung Gmbh | The treatment of the vascular complications of diabetes |
| AT510585B1 (de) * | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
| US11161881B2 (en) * | 2010-11-18 | 2021-11-02 | Apeptico Forschung Und Entwicklung Gmbh | Composition comprising a peptide and an inhibitor of viral neuraminidase |
| EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
| US12004506B2 (en) | 2013-04-23 | 2024-06-11 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| CN105188735A (zh) * | 2013-04-23 | 2015-12-23 | 阿佩普蒂科研究和开发有限责任公司 | 包含式x1-gqretpegaeakpwy-x2的环肽的药物组合物及其体外处理肺的用途 |
| CA2940351A1 (en) | 2014-03-18 | 2015-09-24 | Apeptico Forschung Und Entwicklung Gmbh | Dry-powder peptide medicament |
| CN110613838A (zh) * | 2018-06-19 | 2019-12-27 | 姜石松 | 增强细胞通透性的多肽及其应用 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| IL294894A (en) | 2020-05-08 | 2022-09-01 | Apeptico Forschung & Entwicklung Gmbh | A peptide for the prevention or treatment of covid-19 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE384179C (de) * | 1921-04-07 | 1923-10-27 | Ludwig Weil Dr | Laufrad fuer Kreiselpumpen und -geblaese |
| DE3841759A1 (de) | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
| US5891679A (en) | 1993-02-03 | 1999-04-06 | N.V. Innogenetics S.A. | TNF-alpha muteins and a process for preparing them |
| HU227661B1 (hu) | 1998-08-14 | 2011-10-28 | Rudolf Lucas Dr | TNF-eredetû peptidek ödéma kezelésére |
-
1999
- 1999-08-10 HU HU0103117A patent/HU227661B1/hu not_active IP Right Cessation
- 1999-08-10 TR TR2001/00338T patent/TR200100338T2/xx unknown
- 1999-08-10 JP JP2000564651A patent/JP4542266B2/ja not_active Expired - Lifetime
- 1999-08-10 DK DK02077256T patent/DK1264599T3/da active
- 1999-08-10 CZ CZ20010538A patent/CZ302862B6/cs not_active IP Right Cessation
- 1999-08-10 WO PCT/EP1999/005806 patent/WO2000009149A1/en not_active Ceased
- 1999-08-10 EP EP99942835A patent/EP1105152A1/en not_active Withdrawn
- 1999-08-10 AT AT02077274T patent/ATE395072T1/de active
- 1999-08-10 PT PT02077256T patent/PT1264599E/pt unknown
- 1999-08-10 AU AU56209/99A patent/AU764992B2/en not_active Ceased
- 1999-08-10 BR BR9912899-3A patent/BR9912899A/pt active Search and Examination
- 1999-08-10 DE DE69938743T patent/DE69938743D1/de not_active Expired - Lifetime
- 1999-08-10 AT AT02077256T patent/ATE374039T1/de active
- 1999-08-10 IL IL14106499A patent/IL141064A0/xx unknown
- 1999-08-10 EP EP02077274A patent/EP1247531B1/en not_active Expired - Lifetime
- 1999-08-10 ES ES02077256T patent/ES2296872T3/es not_active Expired - Lifetime
- 1999-08-10 DE DE69937206T patent/DE69937206T2/de not_active Expired - Lifetime
- 1999-08-10 NZ NZ509604A patent/NZ509604A/en not_active IP Right Cessation
- 1999-08-10 CN CNB998096555A patent/CN1181886C/zh not_active Expired - Lifetime
- 1999-08-10 PL PL345997A patent/PL203706B1/pl unknown
- 1999-08-10 EP EP02077256A patent/EP1264599B1/en not_active Expired - Lifetime
- 1999-08-10 CA CA2334941A patent/CA2334941C/en not_active Expired - Lifetime
-
2001
- 2001-01-23 ZA ZA2001/00656A patent/ZA200100656B/en unknown
- 2001-01-24 IL IL141064A patent/IL141064A/en not_active IP Right Cessation
- 2001-02-09 US US09/779,703 patent/US20030105021A1/en not_active Abandoned
-
2002
- 2002-06-06 US US10/162,553 patent/US7258861B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL345997A1 (en) | Tnf-derived peptides for use in treating oedema | |
| IL161591A0 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| WO2003008443A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| HUT54213A (en) | Process for the enzymatic removal of n-terminal sequence of proteins | |
| CA2380690A1 (en) | Human osteoclast-derived cathepsin | |
| AU2672900A (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
| IL187907A0 (en) | Analogues of glp-1 and uses thereof | |
| IL143481A0 (en) | Glp-1 analogues | |
| WO2002015922A3 (en) | New uses for amino acid anticonvulsants for treatment of pain | |
| WO2002097030A3 (en) | Peptides derived from neural thread proteins and their medical use | |
| GB2367061A (en) | Peptides | |
| AR002742A1 (es) | Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn | |
| GR3015817T3 (en) | Substituted alpha-amino acids having pharmaceutical activity. | |
| AU671989B2 (en) | Treatment of tropical spastic paresis with peptide T | |
| DE602004016834D1 (de) | Zusammensetzung zur vermeidung und behandlung von cellulitis | |
| DK0769056T3 (da) | Ikke-splejsende verianter af gp350/220 | |
| DE69734644D1 (de) | Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren | |
| ATE218334T1 (de) | Verwendung von gabapentin in der behandlung vonangst - und panikstörungen | |
| EP1714979A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |